FRANKFURT (Reuters) - A new stroke prevention drug developed by Bayer and Johnson & Johnson proved a safe alternative to the standard treatment, lifting their chances of entering a $12 billion plus market, the German drug company said.
FRANKFURT (Reuters) - A new stroke prevention drug developed by Bayer and Johnson & Johnson proved a safe alternative to the standard treatment, lifting their chances of entering a $12 billion plus market, the German drug company said.
